Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TCRX
#4285
TScan Therapeutics, Inc. Common Stock
1.0
6
USD
+3.92%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+3.92%
Mudança mensal
-2.75%
Mudança em 6 meses
-50.00%
Mudança anual
-13.11%
Fechamento anterior
1.0
2
Abrir
1.0
6
Bid
Ask
Mínimo
1.0
6
High
1.0
6
Volume
8
Mercados
Ações
Cuidados de saúde
TCRX
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
52.63 M
—
Valuation ratios
Enterprise value
-53.51 M
-1.41 M
204.72 M
77.73 M
-5.64 M
16.32 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-1
-5.26
Price to sales ratio
—
3.25
21.72
120.9
12.57
143.87
Price to cash flow ratio
—
-0.62
-6.1
-3.07
-0.96
-5.5
Price to book ratio
—
0.41
2.48
1.41
1.05
1.72
Enterprise value to EBITDA ratio
1.18
0.07
-7.21
-2.48
-0.11
-2.05
Profitability ratios
Return on assets %
-0.26
-0.33
-0.33
-0.34
-0.57
-0.46
Return on equity %
-0.3
-0.67
-0.59
-0.53
-1.05
-0.81
Return on invested capital %
-350.58
-290.57
-270.29
-374.26
-584.75
—
Gross margin %
100
107.12
122.03
100
100
400
Operating margin %
-479.65
-527.39
-541.82
-4 787.68
-1 315.38
-5 331.34
EBITDA margin %
-446.83
-493.86
-532.77
-4 641.8
-1 287.62
-5 218.7
Net margin %
-479.49
-524.11
-517.24
-4 527.66
-1 256.81
-5 090.48
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
8.41
30.46
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.05
0.07
0.07
0.01
0.03
0.04
Solvency ratios
Debt to assets ratio
—
0.43
0.33
0.26
0.41
1.33
Debt to equity ratio
—
0.86
0.59
0.4
0.76
2.33
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.14
0.47
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.26
0.83
Per share metrics
Operating cash flow per share
—
-2.77
-0.94
-0.99
-1.04
-1.04
EBIT per share
—
-2.81
-1.48
-1.2
-1.05
-1.05
EBITDA per share
—
-2.59
-1.4
-1.17
-1.02
-1.02
Total debt per share
—
3.58
1.36
0.87
0.73
2.82
Cash per share
—
4.99
2.93
2.59
1.17
6.22
Net current asset value per share
—
5.16
2.96
2.61
1.21
6.33
Tangible book value per share
—
4.13
2.3
2.15
0.95
5.04
Working capital per share
—
4.44
2.51
2.29
1.07
5.49
Book value per share
—
4.13
2.3
2.15
0.95
5.04
Notícias
H.C. Wainwright reitera recomendação de compra para Tscan com preço-alvo de US$ 7
TScan Therapeutics anuncia renúncia do vice-presidente de finanças
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com
Lucro da Tscan Therapeutics superou projeções por $0,09; receita supera estimativas
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)